Fair Value Calculator Fair Value Calculator
EN DE

ELEMARB (ELEMARB) Fair Value & Analysis

IN · Market cap ₹560M

E ELEMARB ELEMARB · BSE
Price₹188.85
Fair Value₹226.22
Upside+19.8%
Quality55/100
Watch ELEMARB for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹169.66 – ₹253.11

Fair value as of: Jul 5, 2026

From 15 valuation models · updated today

Share price −1.1% over the past month.

Price vs Fair Value (12 months)

₹249.00 ₹147.10 Fair Value ₹226.22 Jul 2025 Jul 2026

12‑month range ₹147.10 – ₹249.00 · fair‑value band ₹169.66 – ₹253.11 · the ₹188.85 price screens below the ₹226.22 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

ELEMARB (ELEMARB) currently trades at ₹188.85, while our model-based Fair Value estimate is ₹226.22 — implying the stock looks roughly 19.8% undervalued today. We read business quality at 55/100 (solid quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, ELEMARB generated revenue of ₹354M at a net margin of 9.5%. Revenue grew 30.0% year over year. It earns a return on equity of 2.5%. The stock trades on a trailing P/E of 16.7. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹169.66 (bear case) to ₹253.11 (bull case); at ₹188.85, the current price sits within that range. The share trades about 28% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹354M
Revenue growth (YoY) +30.0%
Net margin 9.5%
Return on equity 2.5%
Free cash flow −₹11.7M FY2026
P/E ratio 16.7
More key figures
Operating margin 16.1%
EPS (TTM) ₹11.31
EPS growth (YoY) -51.8%

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

ELEMARB reported revenue of ₹338M in FY2026 versus ₹273M in FY2022, a compound +5.5%/yr. Reported net income was ₹33.5M in FY2026, compounding +5.7%/yr from FY2022.

Revenue +5.5%/yr
FY22 ₹273M
FY23 ₹350M
FY24 ₹327M
FY25 ₹268M
FY26 ₹338M
Net income +5.7%/yr
FY22 ₹26.9M
FY23 ₹30.4M
FY24 ₹40.5M
FY25 ₹47.0M
FY26 ₹33.5M

Is ELEMARB fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "ELEMARB Fair Value". https://www.fairvalue-calculator.com/stock/ELEMARB

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is ELEMARB (ELEMARB) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹226.22 versus a price of ₹188.85 — about +20% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ELEMARB?
Our model-based fair value for ELEMARB is ₹226.22 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹188.85.
What is the quality score of ELEMARB?
ELEMARB has a Quality Score of 55/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of ELEMARB (ELEMARB)?
ELEMARB reported trailing-twelve-month revenue of about ₹354M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of ELEMARB?
The net profit margin of ELEMARB is about 9.5%, meaning it keeps roughly 9.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.